Rapid VAC high dose melphalan regimen, a novel chemotherapy approach in childhood soft tissue sarcomas View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1991-08

AUTHORS

CR Pinkerton, J Groot-Loonen, A Barrett, ST Meller, D Tait, S Ashley, TJ McElwain

ABSTRACT

Forty-three children with malignant soft tissue sarcomas (IRS Groups II-IV) were treated with rapid dose delivery chemotherapy protocol comprising six courses of vincristine, adriamycin and cyclophosphamide, given in most cases within 8 weeks (Rapid VAC). This was followed in 36 patients by high dose melphalan with autologous bone marrow rescue. Twenty-six patients also received irradiation to the site of primary tumour. The Rapid VAC regimen was well tolerated and largely administered as an out-patient. There was one toxic death which occurred 2 months after high dose melphalan due to a combination of infection and possible anthracycline cardiomyopathy. Stages were, (Intergroup Rhabdomyosarcoma Study (IRS) system) Group, Group II--four patients. Group III--27 patients and Group IV--12 patients; International Society of Paediatric Oncology (SIOP) staging, Stage I--11, Stage II--13, Stage III--7, Stage IV--12. Actuarial survival at 5 years for all stages is 57% and event free survival 44%. For patients with non-metastatic diseases, 62% and 53% respectively. This treatment strategy utilises the philosophy of rapid drug delivery with high dose consolidation and enables all chemotherapy to be finished within a 4 month period. In general, a conservative approach was applied to both radiation and surgery to minimise late sequelae related to these treatment modalities. Although the small number of high risk patients in this study limits conclusions regarding efficacy in these subgroups the overall results with this regimen appear to be comparable to that with other approaches. More... »

PAGES

381-385

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/bjc.1991.313

DOI

http://dx.doi.org/10.1038/bjc.1991.313

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1018980915

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/1892770


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child, Preschool", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclophosphamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dactinomycin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sarcoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Soft Tissue Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vincristine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Children's Unit, Royal Marsden Hospital, Sutton, UK", 
          "id": "http://www.grid.ac/institutes/grid.424926.f", 
          "name": [
            "Children's Unit, Royal Marsden Hospital, Sutton, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pinkerton", 
        "givenName": "CR", 
        "id": "sg:person.01303612615.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303612615.63"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Groot-Loonen", 
        "givenName": "J", 
        "id": "sg:person.012531667364.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012531667364.86"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Barrett", 
        "givenName": "A", 
        "id": "sg:person.013171347572.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013171347572.53"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Meller", 
        "givenName": "ST", 
        "id": "sg:person.015251342714.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015251342714.32"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Tait", 
        "givenName": "D", 
        "id": "sg:person.0753037103.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753037103.30"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "Ashley", 
        "givenName": "S", 
        "id": "sg:person.01345371112.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01345371112.60"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "McElwain", 
        "givenName": "TJ", 
        "id": "sg:person.01114645401.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114645401.05"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/bjc.1983.175", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027221957", 
          "https://doi.org/10.1038/bjc.1983.175"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1987.108", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043136158", 
          "https://doi.org/10.1038/bjc.1987.108"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1991-08", 
    "datePublishedReg": "1991-08-01", 
    "description": "Forty-three children with malignant soft tissue sarcomas (IRS Groups II-IV) were treated with rapid dose delivery chemotherapy protocol comprising six courses of vincristine, adriamycin and cyclophosphamide, given in most cases within 8 weeks (Rapid VAC). This was followed in 36 patients by high dose melphalan with autologous bone marrow rescue. Twenty-six patients also received irradiation to the site of primary tumour. The Rapid VAC regimen was well tolerated and largely administered as an out-patient. There was one toxic death which occurred 2 months after high dose melphalan due to a combination of infection and possible anthracycline cardiomyopathy. Stages were, (Intergroup Rhabdomyosarcoma Study (IRS) system) Group, Group II--four patients. Group III--27 patients and Group IV--12 patients; International Society of Paediatric Oncology (SIOP) staging, Stage I--11, Stage II--13, Stage III--7, Stage IV--12. Actuarial survival at 5 years for all stages is 57% and event free survival 44%. For patients with non-metastatic diseases, 62% and 53% respectively. This treatment strategy utilises the philosophy of rapid drug delivery with high dose consolidation and enables all chemotherapy to be finished within a 4 month period. In general, a conservative approach was applied to both radiation and surgery to minimise late sequelae related to these treatment modalities. Although the small number of high risk patients in this study limits conclusions regarding efficacy in these subgroups the overall results with this regimen appear to be comparable to that with other approaches.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/bjc.1991.313", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "64"
      }
    ], 
    "keywords": [
      "high-dose melphalan", 
      "dose melphalan", 
      "autologous bone marrow rescue", 
      "malignant soft tissue sarcoma", 
      "courses of vincristine", 
      "bone marrow rescue", 
      "high-dose consolidation", 
      "novel chemotherapy approaches", 
      "non-metastatic disease", 
      "high-risk patients", 
      "soft tissue sarcomas", 
      "combination of infection", 
      "marrow rescue", 
      "VAC regimen", 
      "toxic deaths", 
      "anthracycline cardiomyopathy", 
      "actuarial survival", 
      "melphalan regimen", 
      "late sequelae", 
      "risk patients", 
      "chemotherapy protocols", 
      "tissue sarcomas", 
      "primary tumor", 
      "treatment modalities", 
      "treatment strategies", 
      "chemotherapy approaches", 
      "rapid drug delivery", 
      "stage III", 
      "patients", 
      "stage I", 
      "stage IV", 
      "group II", 
      "stage II", 
      "regimen", 
      "group III", 
      "conservative approach", 
      "soft tissue", 
      "month period", 
      "melphalan", 
      "group IV", 
      "International Society", 
      "most cases", 
      "cyclophosphamide", 
      "chemotherapy", 
      "sequelae", 
      "surgery", 
      "sarcoma", 
      "cardiomyopathy", 
      "vincristine", 
      "tumors", 
      "infection", 
      "staging", 
      "adriamycin", 
      "disease", 
      "drug delivery", 
      "weeks", 
      "months", 
      "death", 
      "efficacy", 
      "survival", 
      "subgroups", 
      "modalities", 
      "children", 
      "small number", 
      "tissue", 
      "overall results", 
      "conclusion", 
      "delivery", 
      "group", 
      "years", 
      "stage", 
      "course", 
      "rescue", 
      "period", 
      "cases", 
      "study", 
      "protocol", 
      "combination", 
      "strategies", 
      "sites", 
      "number", 
      "consolidation", 
      "irradiation", 
      "approach", 
      "results", 
      "radiation", 
      "society", 
      "philosophy"
    ], 
    "name": "Rapid VAC high dose melphalan regimen, a novel chemotherapy approach in childhood soft tissue sarcomas", 
    "pagination": "381-385", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1018980915"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/bjc.1991.313"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "1892770"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/bjc.1991.313", 
      "https://app.dimensions.ai/details/publication/pub.1018980915"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:29", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_257.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/bjc.1991.313"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/bjc.1991.313'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/bjc.1991.313'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/bjc.1991.313'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/bjc.1991.313'


 

This table displays all metadata directly associated to this object as RDF triples.

229 TRIPLES      21 PREDICATES      125 URIs      115 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/bjc.1991.313 schema:about N16576877cbb24784a551c663a99781c6
2 N28abb49525a34709b99f328335dd2326
3 N2a54f21f46424661971cb5e984b96d44
4 N5662dd94ac1c47de8467ffbf776839cc
5 N7bcf6680596348039177f01426e38c18
6 N811ec59dccc945e9b9973c72c30cc759
7 Nb444bf061d0c4cb4a3a84967edd62f1e
8 Ncfbb3232c3f44324995883cec2bd4a69
9 Nd15bf5031a254d8f86874d14bdd1f56b
10 anzsrc-for:11
11 anzsrc-for:1112
12 schema:author Ndc036a150ef349c9b8143cf62c5779f9
13 schema:citation sg:pub.10.1038/bjc.1983.175
14 sg:pub.10.1038/bjc.1987.108
15 schema:datePublished 1991-08
16 schema:datePublishedReg 1991-08-01
17 schema:description Forty-three children with malignant soft tissue sarcomas (IRS Groups II-IV) were treated with rapid dose delivery chemotherapy protocol comprising six courses of vincristine, adriamycin and cyclophosphamide, given in most cases within 8 weeks (Rapid VAC). This was followed in 36 patients by high dose melphalan with autologous bone marrow rescue. Twenty-six patients also received irradiation to the site of primary tumour. The Rapid VAC regimen was well tolerated and largely administered as an out-patient. There was one toxic death which occurred 2 months after high dose melphalan due to a combination of infection and possible anthracycline cardiomyopathy. Stages were, (Intergroup Rhabdomyosarcoma Study (IRS) system) Group, Group II--four patients. Group III--27 patients and Group IV--12 patients; International Society of Paediatric Oncology (SIOP) staging, Stage I--11, Stage II--13, Stage III--7, Stage IV--12. Actuarial survival at 5 years for all stages is 57% and event free survival 44%. For patients with non-metastatic diseases, 62% and 53% respectively. This treatment strategy utilises the philosophy of rapid drug delivery with high dose consolidation and enables all chemotherapy to be finished within a 4 month period. In general, a conservative approach was applied to both radiation and surgery to minimise late sequelae related to these treatment modalities. Although the small number of high risk patients in this study limits conclusions regarding efficacy in these subgroups the overall results with this regimen appear to be comparable to that with other approaches.
18 schema:genre article
19 schema:isAccessibleForFree true
20 schema:isPartOf N447968065c234f15a3958e559dc20839
21 N9726613d26c54d4fa7dfdd3e6d21db77
22 sg:journal.1017082
23 schema:keywords International Society
24 VAC regimen
25 actuarial survival
26 adriamycin
27 anthracycline cardiomyopathy
28 approach
29 autologous bone marrow rescue
30 bone marrow rescue
31 cardiomyopathy
32 cases
33 chemotherapy
34 chemotherapy approaches
35 chemotherapy protocols
36 children
37 combination
38 combination of infection
39 conclusion
40 conservative approach
41 consolidation
42 course
43 courses of vincristine
44 cyclophosphamide
45 death
46 delivery
47 disease
48 dose melphalan
49 drug delivery
50 efficacy
51 group
52 group II
53 group III
54 group IV
55 high-dose consolidation
56 high-dose melphalan
57 high-risk patients
58 infection
59 irradiation
60 late sequelae
61 malignant soft tissue sarcoma
62 marrow rescue
63 melphalan
64 melphalan regimen
65 modalities
66 month period
67 months
68 most cases
69 non-metastatic disease
70 novel chemotherapy approaches
71 number
72 overall results
73 patients
74 period
75 philosophy
76 primary tumor
77 protocol
78 radiation
79 rapid drug delivery
80 regimen
81 rescue
82 results
83 risk patients
84 sarcoma
85 sequelae
86 sites
87 small number
88 society
89 soft tissue
90 soft tissue sarcomas
91 stage
92 stage I
93 stage II
94 stage III
95 stage IV
96 staging
97 strategies
98 study
99 subgroups
100 surgery
101 survival
102 tissue
103 tissue sarcomas
104 toxic deaths
105 treatment modalities
106 treatment strategies
107 tumors
108 vincristine
109 weeks
110 years
111 schema:name Rapid VAC high dose melphalan regimen, a novel chemotherapy approach in childhood soft tissue sarcomas
112 schema:pagination 381-385
113 schema:productId N1a88605775f04b7aa0229c521723ca00
114 N36ea4ae69d024e6b87160fc2e01f3d65
115 Ned71652925a5471e8bd6e0540730677e
116 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018980915
117 https://doi.org/10.1038/bjc.1991.313
118 schema:sdDatePublished 2022-10-01T06:29
119 schema:sdLicense https://scigraph.springernature.com/explorer/license/
120 schema:sdPublisher N595c36dd1e4c440a92ed719b50a1400f
121 schema:url https://doi.org/10.1038/bjc.1991.313
122 sgo:license sg:explorer/license/
123 sgo:sdDataset articles
124 rdf:type schema:ScholarlyArticle
125 N16576877cbb24784a551c663a99781c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Cyclophosphamide
127 rdf:type schema:DefinedTerm
128 N1a88605775f04b7aa0229c521723ca00 schema:name doi
129 schema:value 10.1038/bjc.1991.313
130 rdf:type schema:PropertyValue
131 N28abb49525a34709b99f328335dd2326 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Child, Preschool
133 rdf:type schema:DefinedTerm
134 N2966526f36d044c4aa75741de2f17065 rdf:first sg:person.01114645401.05
135 rdf:rest rdf:nil
136 N2a54f21f46424661971cb5e984b96d44 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Humans
138 rdf:type schema:DefinedTerm
139 N36ea4ae69d024e6b87160fc2e01f3d65 schema:name dimensions_id
140 schema:value pub.1018980915
141 rdf:type schema:PropertyValue
142 N447968065c234f15a3958e559dc20839 schema:issueNumber 2
143 rdf:type schema:PublicationIssue
144 N45202e7e25db494385f55cab40065ea0 rdf:first sg:person.01345371112.60
145 rdf:rest N2966526f36d044c4aa75741de2f17065
146 N49970fbf244e4e71b64bd992e69f7980 rdf:first sg:person.015251342714.32
147 rdf:rest N921e191cac8d4e69b59f7128dc23a591
148 N5662dd94ac1c47de8467ffbf776839cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Dactinomycin
150 rdf:type schema:DefinedTerm
151 N595c36dd1e4c440a92ed719b50a1400f schema:name Springer Nature - SN SciGraph project
152 rdf:type schema:Organization
153 N7bcf6680596348039177f01426e38c18 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Vincristine
155 rdf:type schema:DefinedTerm
156 N7f7a217f75b74a7ab339eb667a46afd3 rdf:first sg:person.012531667364.86
157 rdf:rest N84a6b5f959bd45c6a68fb4f57a61d82c
158 N811ec59dccc945e9b9973c72c30cc759 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Sarcoma
160 rdf:type schema:DefinedTerm
161 N84a6b5f959bd45c6a68fb4f57a61d82c rdf:first sg:person.013171347572.53
162 rdf:rest N49970fbf244e4e71b64bd992e69f7980
163 N921e191cac8d4e69b59f7128dc23a591 rdf:first sg:person.0753037103.30
164 rdf:rest N45202e7e25db494385f55cab40065ea0
165 N9726613d26c54d4fa7dfdd3e6d21db77 schema:volumeNumber 64
166 rdf:type schema:PublicationVolume
167 Nb444bf061d0c4cb4a3a84967edd62f1e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Infant
169 rdf:type schema:DefinedTerm
170 Ncfbb3232c3f44324995883cec2bd4a69 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Soft Tissue Neoplasms
172 rdf:type schema:DefinedTerm
173 Nd15bf5031a254d8f86874d14bdd1f56b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Antineoplastic Combined Chemotherapy Protocols
175 rdf:type schema:DefinedTerm
176 Ndc036a150ef349c9b8143cf62c5779f9 rdf:first sg:person.01303612615.63
177 rdf:rest N7f7a217f75b74a7ab339eb667a46afd3
178 Ned71652925a5471e8bd6e0540730677e schema:name pubmed_id
179 schema:value 1892770
180 rdf:type schema:PropertyValue
181 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
182 schema:name Medical and Health Sciences
183 rdf:type schema:DefinedTerm
184 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
185 schema:name Oncology and Carcinogenesis
186 rdf:type schema:DefinedTerm
187 sg:journal.1017082 schema:issn 0007-0920
188 1532-1827
189 schema:name British Journal of Cancer
190 schema:publisher Springer Nature
191 rdf:type schema:Periodical
192 sg:person.01114645401.05 schema:familyName McElwain
193 schema:givenName TJ
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01114645401.05
195 rdf:type schema:Person
196 sg:person.012531667364.86 schema:familyName Groot-Loonen
197 schema:givenName J
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012531667364.86
199 rdf:type schema:Person
200 sg:person.01303612615.63 schema:affiliation grid-institutes:grid.424926.f
201 schema:familyName Pinkerton
202 schema:givenName CR
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303612615.63
204 rdf:type schema:Person
205 sg:person.013171347572.53 schema:familyName Barrett
206 schema:givenName A
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013171347572.53
208 rdf:type schema:Person
209 sg:person.01345371112.60 schema:familyName Ashley
210 schema:givenName S
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01345371112.60
212 rdf:type schema:Person
213 sg:person.015251342714.32 schema:familyName Meller
214 schema:givenName ST
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015251342714.32
216 rdf:type schema:Person
217 sg:person.0753037103.30 schema:familyName Tait
218 schema:givenName D
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753037103.30
220 rdf:type schema:Person
221 sg:pub.10.1038/bjc.1983.175 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027221957
222 https://doi.org/10.1038/bjc.1983.175
223 rdf:type schema:CreativeWork
224 sg:pub.10.1038/bjc.1987.108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043136158
225 https://doi.org/10.1038/bjc.1987.108
226 rdf:type schema:CreativeWork
227 grid-institutes:grid.424926.f schema:alternateName Children's Unit, Royal Marsden Hospital, Sutton, UK
228 schema:name Children's Unit, Royal Marsden Hospital, Sutton, UK
229 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...